To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma

NCT06298266 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Relapsed or Refractory Multiple Myeloma

Interventions

BIOLOGICAL: infusion of GPRC5D-CD19 CAR T injection

Sponsor

Guangdong Second Provincial General Hospital